Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.

Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.

Huawei’s venture capital arm Hubble Technologies is in line for an exit less than nine months after it invested in fabless semiconductor maker 3Peak.

PMV Pharmaceuticals – built on foundational work at Princeton – will use some of the proceeds to complete phase 1 trials of its lead asset.

Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.

The SIG-backed, MENA-focused chatroom app developer has filed to raise up to $100m in an offering on the New York Stock Exchange.

Boston Scientific owns more than 30% of the emphysema treatment device developer, which is targeting $86.3m in its offering.

QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.

UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

The solid-state battery developer, which has raised $300m from Volkswagen since 2018, will list on the New York Stock Exchange through a reverse merger deal.